US & EU Large Cap Pharma 2016 Outlook Review

Large Cap Pharma Us & Eu Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth

Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Oncology segment has been the key areas of interest for large cap Pharma companies in 2014/2015. The field of immuno-oncology is currently one of the most explosive fields in biotechnology. Bristol-Myers’s with more concentrated effort in Immuno-Oncology has gain the leadership with its Anti-PD-1 drug. Along with Bristol, there’s Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN) as well chasing the field.

View complete report @ http://www.reportsweb.com/large-cap-pharma-us-and-eu-outlook-2016 . 

The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. Anti-Infective remains a big attraction for large pharm. Merck acquisition of Cubist for $9 billion and Roche’ in-licensing deal for $1billion was the key highlight. Biosimilar development from Large ad Biotech companies are progressing well with many reaching to regulatory space and in lates stage of clinical trials. Biogen Idec streamlined its focus to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimer’s disease, Parkinson’s, ALS, Neuro-immunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and Neuropathic Pain). Celgene (CELG) keeps capitalizing on its strength in hematology and operational excellence to build global standards of care in the segments of Oncology and Inflammation & Immunology (I&I). Gilead, a prominent player in Hepatitis C therapy areas is looking to expand its learning in Liver disease for another high unmet need of Nonalcoholic Steatohepatitis (NASH), while its Oncolgy segment failed to make any major impact other than approved drug Zydelig.

First – in-class mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors continue to get attraction by large cap pharma companies. Biotech and pharmaceutical companies pursue targeted and specialized therapies – more than 25% (45 new drugs approval vs. 44 in 2014) of drugs approved by FDA in 2015 are Personalized Medicines. Global Biopharmaceutical Outlook 2016-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.

Request a sample copy @ http://www.reportsweb.com/inquiry&RW0001173056/sample . 

Points from ToC:

CELGENE : Innovative Strategies for Long Term Gains

KEY MILESTONES 
-Development In Multiple Myeloma Franchise: Strengthening Pipeline and Sales
-Inflammation – Pipeline maturing beyond OTEZLA
-Other Products in Mid stage for Long Term Growth
Celegene: Table 1 RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RECENTLY APPROVED – DATA COMPARISON
GILEAD SCIENCES Poised to Emerge as a Leader in HCV Treatment!
Table 1 Gilead Sciences DEVELOPMENT PIPELINE
Table 2 Gilead Sciences DATA FROM ASTRAL -1 STUDY
Table 3 Gilead Sciences DATA FROM ASTRAL-4 STUDY
- GILD has multiple programs running in late stage PhII/PhIII chronic HBV pts
-Liver Disease – Non-alcoholic Hepatosteatosis (NASH)
- Inflammation/Respiratory Pipeline

- ACQUISITIONS IN THE LAST ONE YEAR

Contact [email protected] for more details, call us at +1-646-491-9876 .